XNASABVC
Market cap7mUSD
Dec 27, Last price
0.58USD
1D
3.97%
1Q
-15.44%
Jan 2017
-70.94%
Name
ABVC Biopharma Inc
Chart & Performance
P/E
—
P/S
49.47
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
29.55%
Rev. gr., 5y
85.41%
Revenues
152k
-84.28%
Net income
-11m
L-35.54%
CFO
-4m
L-42.75%
Earnings
Mar 11, 2025
Profile
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑09 | 2015‑09 | |
| Income | |||||||||
Revenues | 152 -84.28% | 970 172.57% | 356 -26.34% | ||||||
Cost of revenue | 8,369 | 16,084 | 12,062 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (8,217) | (15,114) | (11,706) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 256 | 798 | 825 | ||||||
Tax Rate | |||||||||
NOPAT | (8,473) | (15,912) | (12,531) | ||||||
Net income | (10,516) -35.54% | (16,312) 35.53% | (12,036) 13.61% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,050 | 3,664 | 11,119 | ||||||
BB yield | -20.88% | -185.14% | -130.92% | ||||||
| Debt | |||||||||
Debt current | 1,871 | 2,263 | 1,987 | ||||||
Long-term debt | 1,217 | 1,953 | 2,597 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 22 | (372) | 11 | ||||||
Net debt | 420 | 374 | (2,286) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (4,236) | (7,398) | (7,598) | ||||||
CAPEX | (21) | (120) | (18) | ||||||
Cash from investing activities | (360) | (1,722) | (806) | ||||||
Cash from financing activities | 3,919 | 4,014 | 9,996 | ||||||
FCF | (13,793) | (13,097) | (14,224) | ||||||
| Balance | |||||||||
Cash | 139 | 161 | 5,937 | ||||||
Long term investments | 2,528 | 3,681 | 933 | ||||||
Excess cash | 2,660 | 3,793 | 6,852 | ||||||
Stockholders' equity | (65,161) | (53,837) | (37,886) | ||||||
Invested Capital | 75,591 | 60,136 | 49,879 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 4,336 | 3,166 | 2,505 | ||||||
Price | 1.16 85.60% | 0.63 -81.56% | 3.39 -33.53% | ||||||
Market cap | 5,029 154.13% | 1,979 -76.70% | 8,493 -15.53% | ||||||
EV | 5,192 | 2,870 | 6,234 | ||||||
EBITDA | (8,188) | (15,091) | (11,694) | ||||||
EV/EBITDA | |||||||||
Interest | 2,493 | 294 | 227 | ||||||
Interest/NOPBT | |||||||||